X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CD14152 (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, which is being evaluated for the treatment of patients with prurigo nodularis & for adolescents and adults with moderate to severe atopic dermatitis.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: CD14152
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
QM1114-DP (relabotulinumtoxinA) is a botulinum toxin neuromodulator, which is under phase 3 clinical development for the treatment of glabellar frown lines & lateral canthal lines.
Lead Product(s): RelabotulinumtoxinA
Therapeutic Area: Dermatology Product Name: QM1114-DP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
QM1114-DP (RelabotulinumtoxinA) is a rapid and long lasting small molecule injection formulation, which is being investigated for dermatological conditions like Crow’s Feet and Frown Lines.
Lead Product(s): RelabotulinumtoxinA
Therapeutic Area: Dermatology Product Name: QM1114-DP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
Under the termination, Ipsen will retain all rights and obligations related to its early-stage R&D neurotoxin pipeline, including the development of IPN10200 (abobotulinumtoxinA), for the treatment of upper facial lines and muscle spasticity.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: IPN10200
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Ipsen
Deal Size: $41.1 million Upfront Cash: $13.7 million
Deal Type: Termination July 27, 2023
Details:
Sculptra is the first and original injectable collagen stimulator containing microparticles of unique poly-L-lactic acid (PLLA-SCA) which gradually revitalizes the skin’s structural foundation.
Lead Product(s): L-Lactic Acid,Sodium Carboxymethylcellulose
Therapeutic Area: Dermatology Product Name: Sculptra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
Alluzience (abobotulinumtoxinA solution) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: Alluzience
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
RelabotulinumtoxinA is a highly-active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a proprietary strain, manufactured using a state-of-the-art, unique process.
Lead Product(s): BotulinumtoxinA
Therapeutic Area: Dermatology Product Name: RelabotulinumtoxinA
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
CD14152 (nemolizumab) is a first-in-class investigational monoclonal antibody that blocks the signaling of IL-31, a key neuroimmune cytokine involved in the pathogenesis of prurigo nodularis.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: CD14152
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
Patients treated with CD14152 (nemolizumab) monotherapy (without background topical corticosteroids or topical calcineurin inhibitors) showed clinically and statistically significant improvement in both primary endpoints compared to placebo after 16 weeks of treatment.
Lead Product(s): Nemolizumab
Therapeutic Area: Dermatology Product Name: CD14152
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Chugai Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
BotulinumtoxinA (RelabotulinumtoxinA) is designed as a liquid, avoiding the traditional requirement to reconstitute from powder, eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results.
Lead Product(s): BotulinumtoxinA
Therapeutic Area: Dermatology Product Name: RelabotulinumtoxinA
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
